Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
Ren Fail ; 32(8): 992-9, 2010.
Article in English | MEDLINE | ID: mdl-20722568

ABSTRACT

AIM: The aim of this study is to investigate the efficacy and mechanism of action of intravenous (IV) bicarbonate in preventing radiocontrast nephropathy (RCN). MATERIALS AND METHODS: Twenty-eight Wistar rats were randomized into four groups including control (group 1), radiocontrast (group 2), bicarbonate (group 3), and radiocontrast plus bicarbonate (group 4). Once blood chemistry and arterial blood gases were examined and 24 h urine samples were collected, all rats were administered furosemide (2 mg/kg subcutaneous) and deprived of water for 24 h. Iothalamate sodium (6 mL/kg) was administered to group 2 and group 4. IV bicarbonate (8.4%) was administered to group 3 and group 4 (3 h before the administration of iothalamate). On the fourth day, 24 h urine was collected, and at the end of the day rats were sacrificed and blood chemistry and arterial blood gases were reexamined. Myeloperoxidase (MPO), nitric oxide (NO), total glutathione, and malondialdehyde were quantified on the renal tissue. H&E slides were examined. RESULTS: Basal creatinine and creatinine clearance were similar between groups. There was no significant difference between creatinine and creatinine clearance by the end of the experiment. Glutathione level in group 2 was lower than in group 4. Histopathologically, there was no injury in the control group (group 1) whereas there was an intermediate-severe injury (71.4%) in the radiocontrast group (group 2). The percentage of intermediate-severe injury was significantly lower (71.4% vs. 28.6%, p = 0.02) in the radiocontrast plus bicarbonate group (group 4). CONCLUSIONS: Sodium bicarbonate attenuates the development of radiocontrast-induced tubular necrosis.


Subject(s)
Contrast Media/adverse effects , Ioxaglic Acid/adverse effects , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , Sodium Bicarbonate/therapeutic use , Animals , Disease Models, Animal , Female , Infusions, Intravenous , Kidney Diseases/pathology , Kidney Function Tests , Oxidative Stress , Rats , Rats, Wistar
3.
BJU Int ; 90(4): 442-5, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12175405

ABSTRACT

OBJECTIVE: To assess the efficacy of sildenafil for erectile dysfunction (ED) in patients on haemodialysis (HD) or peritoneal dialysis (PD), as men with end-stage renal disease (ESRD) often have sexual dysfunction (up to 82% among those on chronic dialysis). PATIENTS AND METHODS: Forty-one patients with ED and in ESRD participated in an open-label prospective study. Thirty patients on HD and 11 on PD were asked to complete the International Index of Erectile Function (IIEF) and Fugl-Meyer life-satisfaction scale before and after sildenafil treatment. A total score in the erectile function domain of < or = 25 was accepted as indicating ED. All patients were started on a 25-mg dose, which was increased to 50 mg if there was no response after two trials. In addition, the overall efficacy question was used to evaluate satisfaction, and patients reported any side-effects during treatment. RESULTS: The erectile function and intercourse satisfaction domains improved significantly in both groups (P < 0.01). After sildenafil treatment, two-thirds of those on HD (20/30) and nine of the 11 on PD recovered their erectile function. The pretreatment scores on the IIEF and four domains (except sexual desire) of those responding were significantly higher than in those not responding (P < 0.05). The satisfaction rate on the overall efficacy question was 80% and 82% for the HD and PD groups, respectively. At least one side-effect was seen in 17 patients (43%); one had severe hypotension in the PD group. Overall, mild headache (seven patients, 18%) and flushing (12, 30%) were reported most often. CONCLUSIONS: Sildenafil is a safe and satisfactory drug for improving erectile function in patients with ESRD. Patients were satisfied whether treated by HD or PD. Pretreatment scores on the IIEF may be useful for predicting the success of treatment.


Subject(s)
Erectile Dysfunction/drug therapy , Kidney Failure, Chronic/complications , Phosphodiesterase Inhibitors/therapeutic use , Piperazines/therapeutic use , Renal Dialysis , Adult , Aged , Erectile Dysfunction/complications , Humans , Kidney Failure, Chronic/therapy , Male , Middle Aged , Patient Satisfaction , Peritoneal Dialysis , Prospective Studies , Purines , Quality of Life , Sexual Behavior , Sildenafil Citrate , Sulfones
5.
Scand J Urol Nephrol ; 34(2): 126-30, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10903075

ABSTRACT

OBJECTIVES: Hypoxaemia occurring during haemodialysis has long been known. Several mechanisms in the pathogenesis have been proposed. The present study was conducted to test whether changes in pulmonary alveolar permeability were among the operating mechanisms. MATERIALS AND METHODS: Twenty haemodialysis patients (12 male, 8 female) were included in the study. The mean age was 49 years (age range: 18-85 years). Patients with known pulmonary disease, current smokers and those gaining more than 1 kg weight during the interdialytic period were excluded. Complete blood count, arterial blood gas analysis, pulmonary function tests and Tc-99m diethylene triamine pentaacetate (DTPA) inhalation scintiscan were carried out before and after haemodialysis. A bronchial provocation test was carried out after each session. A postero-anterior chest radiogram was taken for each patient. RESULTS: When the results before and after haemodialysis were compared, it was observed that the pH and serum bicarbonate levels, haemoglobin and haematocrit values were significantly higher after haemodialysis. However, the platelet count was found to be decreased significantly. Bronchial hyperreactivity, tested by metacholine, Was positive in 5 of 19 patients (26%). No correlation between bronchial hyperreactivity and other factors could be identified. No significant difference was observed in pulmonary Tc-99m DTPA clearance after haemodialysis. All chest radiograms were interpreted to be within normal limits. CONCLUSIONS: Since we observed no hypoxaemia following haemodialysis, we cannot comment as to whether the changes in pulmonary clearance play a role in the pathogenesis of haemodialysis-associated hypoxaemia. In order to reach reliable conclusions, additional studies are needed.


Subject(s)
Pulmonary Alveoli/metabolism , Renal Dialysis , Technetium Tc 99m Pentetate/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged
6.
Clin Rheumatol ; 17(5): 397-9, 1998.
Article in English | MEDLINE | ID: mdl-9805187

ABSTRACT

Familial Mediterranean fever (FMF) and Behçet's disease are relatively rare but may still coexist in the same patient. Sacroiliitis is another feature whose significance is controversial in either of the diseases. We report a case of longstanding FMF with sacroiliitis who later developed typical characteristics of Behçet's disease. Although occurrence by chance cannot be ruled out, this unusual patient may enhance the claims that FMF and Behçet's disease have common aetiopathogenetic mechanisms. It would be appropriate to include this coexistence in the list of differential diagnoses of the two diseases.


Subject(s)
Arthritis/complications , Behcet Syndrome/complications , Familial Mediterranean Fever/complications , Sacroiliac Joint , Adult , Arthritis/pathology , Behcet Syndrome/pathology , Familial Mediterranean Fever/pathology , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...